Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors

J. Gerardo García-Lerma, Wutyi Aung, Mian Er Cong, Qi Zheng, Ae S. Youngpairoj, James Mitchell, Angela Holder, Amy Martin, Susan Kuklenyik, Wei Luo, Carol Yen Chin Lin, Debra L. Hanson, Ellen Kersh, Chou Pong Pau, Adrian S. Ray, James F. Rooney, William A. Lee, Walid Heneine

Research output: Contribution to journalArticle

Abstract

Preexposure prophylaxis (PrEP) with antiretroviral drugs is a novel human immunodeficiency virus (HIV) prevention strategy. It is generally thought that high systemic and mucosal drug levels are sufficient for protection. We investigated whether GS7340, a next-generation tenofovir (TFV) prodrug that effectively delivers tenofovir diphosphate (TFV-DP) to lymphoid cells and tissues, could protect macaques against repeated weekly rectal simian-human immunodeficiency virus (SHIV) exposures. Macaques received prophylactic GS7340 treatment 3 days prior to each virus exposure. At 3 days postdosing, TFV-DP concentrations in peripheral blood mononuclear cells (PBMCs) were about 50-fold higher than those seen with TFV disoproxil fumarate (TDF), and they remained above 1,000 fmol/106 cells for as long as 7 days. TFV-DP accumulated in lymphoid and rectal tissues, with concentrations at 3 days exceeding 500 fmol/106 mononuclear cells. Despite high mucosal and systemic TFV levels, GS7340 was not protective. Since TFV-DP blocks reverse transcription by competing with the natural dATP substrate, we measured dATP contents in peripheral lymphocytes, lymphoid tissue, and rectal mononuclear cells. Compared to those in circulating lymphocytes and lymphoid tissue, rectal lymphocytes had 100-fold higher dATP concentrations and dATP/TFV-DP ratios, likely reflecting the activated status of the cells and suggesting that TFV-DP may be less active at the rectal mucosa. Our results identify dATP/TFV-DP ratios as a possible correlate of protection by TFV and suggest that natural substrate concentrations at the mucosa will likely modulate the prophylactic efficacy of nucleotide reverse transcriptase inhibitors.

Original languageEnglish (US)
Pages (from-to)6610-6617
Number of pages8
JournalJournal of Virology
Volume85
Issue number13
DOIs
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Tenofovir
HIV Reverse Transcriptase
Reverse Transcriptase Inhibitors
RNA-directed DNA polymerase
Human immunodeficiency virus
Nucleotides
nucleotides
lymphocytes
Lymphoid Tissue
Macaca
mucosa
cells
Lymphocytes
reverse transcription
mononuclear leukocytes
disease control
Mucous Membrane
HIV
drugs
Simian Immunodeficiency Virus

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

García-Lerma, J. G., Aung, W., Cong, M. E., Zheng, Q., Youngpairoj, A. S., Mitchell, J., ... Heneine, W. (2011). Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. Journal of Virology, 85(13), 6610-6617. https://doi.org/10.1128/JVI.00311-11

Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. / García-Lerma, J. Gerardo; Aung, Wutyi; Cong, Mian Er; Zheng, Qi; Youngpairoj, Ae S.; Mitchell, James; Holder, Angela; Martin, Amy; Kuklenyik, Susan; Luo, Wei; Lin, Carol Yen Chin; Hanson, Debra L.; Kersh, Ellen; Pau, Chou Pong; Ray, Adrian S.; Rooney, James F.; Lee, William A.; Heneine, Walid.

In: Journal of Virology, Vol. 85, No. 13, 07.2011, p. 6610-6617.

Research output: Contribution to journalArticle

García-Lerma, JG, Aung, W, Cong, ME, Zheng, Q, Youngpairoj, AS, Mitchell, J, Holder, A, Martin, A, Kuklenyik, S, Luo, W, Lin, CYC, Hanson, DL, Kersh, E, Pau, CP, Ray, AS, Rooney, JF, Lee, WA & Heneine, W 2011, 'Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors', Journal of Virology, vol. 85, no. 13, pp. 6610-6617. https://doi.org/10.1128/JVI.00311-11
García-Lerma, J. Gerardo ; Aung, Wutyi ; Cong, Mian Er ; Zheng, Qi ; Youngpairoj, Ae S. ; Mitchell, James ; Holder, Angela ; Martin, Amy ; Kuklenyik, Susan ; Luo, Wei ; Lin, Carol Yen Chin ; Hanson, Debra L. ; Kersh, Ellen ; Pau, Chou Pong ; Ray, Adrian S. ; Rooney, James F. ; Lee, William A. ; Heneine, Walid. / Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. In: Journal of Virology. 2011 ; Vol. 85, No. 13. pp. 6610-6617.
@article{93f75619c9504cf79e19da27f1d1b671,
title = "Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors",
abstract = "Preexposure prophylaxis (PrEP) with antiretroviral drugs is a novel human immunodeficiency virus (HIV) prevention strategy. It is generally thought that high systemic and mucosal drug levels are sufficient for protection. We investigated whether GS7340, a next-generation tenofovir (TFV) prodrug that effectively delivers tenofovir diphosphate (TFV-DP) to lymphoid cells and tissues, could protect macaques against repeated weekly rectal simian-human immunodeficiency virus (SHIV) exposures. Macaques received prophylactic GS7340 treatment 3 days prior to each virus exposure. At 3 days postdosing, TFV-DP concentrations in peripheral blood mononuclear cells (PBMCs) were about 50-fold higher than those seen with TFV disoproxil fumarate (TDF), and they remained above 1,000 fmol/106 cells for as long as 7 days. TFV-DP accumulated in lymphoid and rectal tissues, with concentrations at 3 days exceeding 500 fmol/106 mononuclear cells. Despite high mucosal and systemic TFV levels, GS7340 was not protective. Since TFV-DP blocks reverse transcription by competing with the natural dATP substrate, we measured dATP contents in peripheral lymphocytes, lymphoid tissue, and rectal mononuclear cells. Compared to those in circulating lymphocytes and lymphoid tissue, rectal lymphocytes had 100-fold higher dATP concentrations and dATP/TFV-DP ratios, likely reflecting the activated status of the cells and suggesting that TFV-DP may be less active at the rectal mucosa. Our results identify dATP/TFV-DP ratios as a possible correlate of protection by TFV and suggest that natural substrate concentrations at the mucosa will likely modulate the prophylactic efficacy of nucleotide reverse transcriptase inhibitors.",
author = "Garc{\'i}a-Lerma, {J. Gerardo} and Wutyi Aung and Cong, {Mian Er} and Qi Zheng and Youngpairoj, {Ae S.} and James Mitchell and Angela Holder and Amy Martin and Susan Kuklenyik and Wei Luo and Lin, {Carol Yen Chin} and Hanson, {Debra L.} and Ellen Kersh and Pau, {Chou Pong} and Ray, {Adrian S.} and Rooney, {James F.} and Lee, {William A.} and Walid Heneine",
year = "2011",
month = "7",
doi = "10.1128/JVI.00311-11",
language = "English (US)",
volume = "85",
pages = "6610--6617",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "13",

}

TY - JOUR

T1 - Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors

AU - García-Lerma, J. Gerardo

AU - Aung, Wutyi

AU - Cong, Mian Er

AU - Zheng, Qi

AU - Youngpairoj, Ae S.

AU - Mitchell, James

AU - Holder, Angela

AU - Martin, Amy

AU - Kuklenyik, Susan

AU - Luo, Wei

AU - Lin, Carol Yen Chin

AU - Hanson, Debra L.

AU - Kersh, Ellen

AU - Pau, Chou Pong

AU - Ray, Adrian S.

AU - Rooney, James F.

AU - Lee, William A.

AU - Heneine, Walid

PY - 2011/7

Y1 - 2011/7

N2 - Preexposure prophylaxis (PrEP) with antiretroviral drugs is a novel human immunodeficiency virus (HIV) prevention strategy. It is generally thought that high systemic and mucosal drug levels are sufficient for protection. We investigated whether GS7340, a next-generation tenofovir (TFV) prodrug that effectively delivers tenofovir diphosphate (TFV-DP) to lymphoid cells and tissues, could protect macaques against repeated weekly rectal simian-human immunodeficiency virus (SHIV) exposures. Macaques received prophylactic GS7340 treatment 3 days prior to each virus exposure. At 3 days postdosing, TFV-DP concentrations in peripheral blood mononuclear cells (PBMCs) were about 50-fold higher than those seen with TFV disoproxil fumarate (TDF), and they remained above 1,000 fmol/106 cells for as long as 7 days. TFV-DP accumulated in lymphoid and rectal tissues, with concentrations at 3 days exceeding 500 fmol/106 mononuclear cells. Despite high mucosal and systemic TFV levels, GS7340 was not protective. Since TFV-DP blocks reverse transcription by competing with the natural dATP substrate, we measured dATP contents in peripheral lymphocytes, lymphoid tissue, and rectal mononuclear cells. Compared to those in circulating lymphocytes and lymphoid tissue, rectal lymphocytes had 100-fold higher dATP concentrations and dATP/TFV-DP ratios, likely reflecting the activated status of the cells and suggesting that TFV-DP may be less active at the rectal mucosa. Our results identify dATP/TFV-DP ratios as a possible correlate of protection by TFV and suggest that natural substrate concentrations at the mucosa will likely modulate the prophylactic efficacy of nucleotide reverse transcriptase inhibitors.

AB - Preexposure prophylaxis (PrEP) with antiretroviral drugs is a novel human immunodeficiency virus (HIV) prevention strategy. It is generally thought that high systemic and mucosal drug levels are sufficient for protection. We investigated whether GS7340, a next-generation tenofovir (TFV) prodrug that effectively delivers tenofovir diphosphate (TFV-DP) to lymphoid cells and tissues, could protect macaques against repeated weekly rectal simian-human immunodeficiency virus (SHIV) exposures. Macaques received prophylactic GS7340 treatment 3 days prior to each virus exposure. At 3 days postdosing, TFV-DP concentrations in peripheral blood mononuclear cells (PBMCs) were about 50-fold higher than those seen with TFV disoproxil fumarate (TDF), and they remained above 1,000 fmol/106 cells for as long as 7 days. TFV-DP accumulated in lymphoid and rectal tissues, with concentrations at 3 days exceeding 500 fmol/106 mononuclear cells. Despite high mucosal and systemic TFV levels, GS7340 was not protective. Since TFV-DP blocks reverse transcription by competing with the natural dATP substrate, we measured dATP contents in peripheral lymphocytes, lymphoid tissue, and rectal mononuclear cells. Compared to those in circulating lymphocytes and lymphoid tissue, rectal lymphocytes had 100-fold higher dATP concentrations and dATP/TFV-DP ratios, likely reflecting the activated status of the cells and suggesting that TFV-DP may be less active at the rectal mucosa. Our results identify dATP/TFV-DP ratios as a possible correlate of protection by TFV and suggest that natural substrate concentrations at the mucosa will likely modulate the prophylactic efficacy of nucleotide reverse transcriptase inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=80052070000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052070000&partnerID=8YFLogxK

U2 - 10.1128/JVI.00311-11

DO - 10.1128/JVI.00311-11

M3 - Article

VL - 85

SP - 6610

EP - 6617

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 13

ER -